Combination of PARP and DNA methylation inhibitors as a potential personalized therapy for SETD2-mutated clear-cell renal cancers.

ABSTRACT:

SUBMITTER: Shahini A 

PROVIDER: S-EPMC11291424 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature